Alex Gorsky named new chief executive of J&J

pharmafile | February 22, 2012 | Appointment | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Alex Gorsky, J&J, JJ, Janssen, Weldon 

Johnson & Johnson has named Alex Gorsky as its new chief executive, effective from 26 April.

Gorsky was also nominated for election to the board of directors and will replace the long serving Bill Weldon. 

Gorsky will also succeed Weldon, 63, as chairman of the company’s executive committee from April 26.

Gorsky began his Johnson & Johnson career in 1988 as a sales representative with Janssen in the pharmaceuticals business. 

Advertisement

He left the company in 2004 to join the Novartis Pharmaceuticals, where he served as head of the company’s pharma business in North America. 

He returned four years later, as the company’s group chairman and worldwide franchise chairman for Ethicon in the medical devices business. 

His most recent position was as vice chairman of the company’s executive committee with responsibility for the medical devices and diagnostics group, global supply chain, healthcare compliance and government affairs.

Gorsky holds a bachelor of science degree from the US Military Academy at West Point, New York, and spent six years in the US Army.  

In 1996, he earned a master of business administration degree from the Wharton School of the University of Pennsylvania.

Related Content

J&J seek approval for first drug to treat high-risk smoldering myeloma

Earlier in November, Johnson & Johnson innovative medicine have applied to the US Food and …

lungs

European Commission approves combination chemotherapy for treatment of advanced EGFR-mutated non-small cell lung cancer in adult patients

Today, Janssen-Cilag International, part of Johnson & Johnson (J&J) has announced that the European Comission …

Janssen’s study for nipocalimab as indicated for EOS-HDFN published in The New England Journal of Medicine

Johnson & Johnson company Janssen has announced that the results from its phase 2 trial …

The Gateway to Local Adoption Series

Latest content